- published: 21 Aug 2014
- views: 25305
Taltirelin (marketed under the tradename Ceredist) is a thyrotropin-releasing hormone (TRH) analog, which mimics the physiological actions of TRH, but with a much longer half-life and duration of effects, and little development of tolerance following prolonged dosing. It has nootropic,neuroprotective and analgesic effects.
Taltirelin is primarily being researched for the treatment of spinocerebellar ataxia; limited research has also been carried out with regard to other neurodegenerative disorders, e.g., spinal muscular atrophy.
Arch Neurol. 2012;69(1):133. doi: 10.1001/archneurol.2011.717. Read the article here: http://ja.ma/1C8qIsU
Joseph Cotten, MD, PhD ISAP 26th Annual Meeting 2017
Richard Horner, University of Toronto, Canada, gives his talk 'Strategic decision making and potential drug targets for sleep apnea pharmacotherapy' at The Physiological Society 'Sleep and Circadian Rhythms from Mechanisms to Function' conference, 5–6 December 2018, Barbican Centre, London.
Albert Dahan, MD, PhD ISAP 26th Annual Meeting 2017
#에이치엘비 #에이치엘비생명과학 #메디프론제약 에이치엘비그룹이 메디프론제약을 인수했습니다. 에이치에비생명과학이 메디프론제약 유상증자에 참여해 지분 17.19%를 확보하며 최대주주가 됐습니다. 에이치엘비도 100억원 규모의 메디프론제약 전환사채를 인수하기도 했습니다.
Taltirelin (marketed under the tradename Ceredist) is a thyrotropin-releasing hormone (TRH) analog, which mimics the physiological actions of TRH, but with a much longer half-life and duration of effects, and little development of tolerance following prolonged dosing. It has nootropic,neuroprotective and analgesic effects.
Taltirelin is primarily being researched for the treatment of spinocerebellar ataxia; limited research has also been carried out with regard to other neurodegenerative disorders, e.g., spinal muscular atrophy.